Although both M1 and M2 subtypes demonstrate a robust response to CD47-SIRPα disruption, the stronger M1 antitumor response and associated cytokine profile suggest a clinical value from enhancing the M1 macrophage response toward gliomas and other solid tumors [50]. The gene discussed is CD47; the disease is glioma.